Use of carbon-nitrogen fluorescent quantum dots in the production of aerobic glycolysis detection products
Patent Information
- Application Number
- JP2023527458
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-10-29
- Filing Date
- 2021-12-28
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2041-12-28
AI Technical Summary
【0007】 上述したように、本発明の好気的解糖検出製品の製造における炭素-窒素蛍光量子ドットの使用は、以下の有益な効果を有する。即ち、本発明では、炭素-窒素蛍光量子ドットを用いることで生細胞中のNAD+の蛍光標識を実現可能とし、これにより、好気的解糖さ れた細胞の蛍光標識及びイメージングを実現する。よって、低コスト、高効率、迅速、高精度等の優位性を有する。且つ、当該技術は、剥離腫瘍細胞の蛍光識別、腫瘍の超早期警告、腫瘍転移巣の検出、腫瘍の増殖及び悪性度評価等の一連の技術の開発実現に資するものである。
Smart Images

Figure 0007590569000001 
Figure 0007590569000002 
Figure 0007590569000003
Abstract
Description
[Technical field]
[0001] The present invention relates to the field of glycolysis detection, and in particular to the use of carbon-nitrogen fluorescent quantum dots in the production of aerobic glycolysis detection products. [Background technology]
[0002] The aerobic glycolysis process is an important metabolic difference between normal cells and tumor cells. Therefore, fluorescent screening and imaging of aerobic glycolysis at the cellular level is a potentially important means for identifying tumor cells and assessing tumor risk. The detection of aerobic glycolysis is mainly achieved by the detection of NAD + It relies on the detection of NADH or NADH. With the advancement of technology, the direction of detecting specific target metabolites in the glycolysis process has been moving in the direction of detecting specific target metabolites, and there are conventional technical means such as enzyme cycling measurement, chromatography, mass spectrometry, and nuclear magnetic resonance spectroscopy. However, these detection methods have the limitation that they only reflect the average metabolic state of a cell group, and cannot reflect the metabolic state of a single cell. In addition, cell lysate is required, and live cells cannot be detected, making in vivo detection even more impossible. At present, a relatively advanced detection technology is called "genetically encoded metabolite sensors." The principle of this technology is to label metabolites such as NADH, ATP, and glucose by binding them to change their structure and changing the fluorescence intensity (Reference: Non-Patent Document 1). Genetically encoded metabolite sensors detect NAD in cells, and + and NADH dynamics with high sensitivity, but they also have some drawbacks, such as low fluorescence intensity and low specificity (for whole cell NAD + However, they have limitations, such as being highly sensitive to pH (detecting tumors with high pH levels) and being highly sensitive to the acidic tumor microenvironment. [Prior art documents] [Non-patent literature]
[0003] [Non-Patent Document 1] SoNar,a Highly Responsive NAD+ / NADH Sensor,Allows High-Throughput Metabolic Screening of Anti-tumor Agents Summary of the Invention [Problem to be solved by the invention]
[0004] In view of the above-mentioned shortcomings of the prior art, the object of the present invention is to provide the use of carbon-nitrogen fluorescent quantum dots in the manufacture of aerobic glycolysis detection products to solve the problems of the prior art. [Means for solving the problem]
[0005] To achieve the above and other related objects, the present invention provides the use of carbon-nitrogen fluorescent quantum dots in the manufacture of an aerobic glycolysis detection product.
[0006] The present invention further provides a method for detecting aerobic glycolysis, which comprises the steps of co-incubating a test sample with an aerobic glycolysis detection product comprising carbon-nitrogen fluorescent quantum dots, and detecting the presence or absence of fluorescence generation or the intensity of the fluorescence in the test sample after the incubation is completed. Effect of the Invention
[0007] As described above, the use of carbon-nitrogen fluorescent quantum dots in the production of the aerobic glycolysis detection product of the present invention has the following beneficial effects: In the present invention, the carbon-nitrogen fluorescent quantum dots are used to detect NAD in living cells. + This makes it possible to fluorescently label the This technology realizes fluorescent labeling and imaging of exfoliated cells, and thus has advantages such as low cost, high efficiency, speed, and high accuracy. This technology also contributes to the development and realization of a series of technologies such as fluorescent identification of exfoliated tumor cells, ultra-early warning of tumors, detection of tumor metastases, and evaluation of tumor growth and malignancy.
[0008] Next, in combination with the drawings, the concept, specific structure and resulting technical effects of the present invention will be further described so that the objectives, features and effects of the present invention can be fully understood. [Brief description of the drawings]
[0009] [Figure 1] FIG. 1 shows common cellular metabolic products detected by the aerobic glycolysis detection product provided in the present invention. [Diagram 2] FIG. 2 shows the fluorescence excitation wavelengths and fluorescence emission wavelengths of carbon-nitrogen quantum dots, which are the main components of the aerobic glycolysis detection product provided by the present invention, and the metabolic product NAD+. [Diagram 3] FIG. 3 shows the fluorescence quantification curve when the aerobic glycolysis detection product provided by the present invention detects the metabolic product NAD+. [Figure 4] FIG. 4 shows the aerobic glycolysis detection product provided by the present invention detecting the aerobic glycolysis of A375 cells and fibroblasts. [Diagram 5] FIG. 5 shows a fluorescence comparison diagram of the aerobic glycolysis detection product provided by the present invention detecting A375 cells treated with PFK15 and untreated A375 cells. [Figure 6] FIG. 6 shows the fluorescence image of the aerobic glycolysis detection product provided by the present invention detecting tumors in animals. [Figure 7] FIG. 7 shows a fluorescence comparison diagram of the aerobic glycolysis detection product provided by the present invention detecting tumor cells in urine samples. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0010] The present invention provides the use of carbon-nitrogen fluorescent quantum dots in the manufacture of aerobic glycolysis detection products.
[0011] The carbon-nitrogen fluorescent quantum dots (also referred to as nitrogen-doped graphene quantum dots, N-CDs) are selected from one or more of C3N4 quantum dots, C2N quantum dots or C3N quantum dots.
[0012] The N-CDs have a uniform size. In addition, the nitrogen-doped structure of the crystals significantly improves the fluorescence quantum yield of N-CDs, giving them strong and stable photoluminescence properties at 540 nm. In terms of bioimaging, compared with conventional fluorescent contrast agents, N-CDs show obvious advantages such as strong fluorescent signals, high detection sensitivity, excellent stability, good biocompatibility, and the ability to perform dynamic observation and bioimaging over a long period of time.
[0013] Preferably, the carbon-nitrogen fluorescent quantum dots are selected from CN quantum dots, which are single-layer two-dimensional semiconductor quantum materials that are composed of carbon and nitrogen atoms and have a hole-free honeycomb-like ordered structure similar to graphene, and are a new type of indirect bandgap semiconductor.
[0014] In one embodiment, the intrinsic band gap of the CN quantum dots is 0.39 eV. The band gap can be tuned by nano-size effects. The on-off ratio of a FET device based on a single CN thin film is 5.5×10 10 The carrier mobility can reach up to 220 cm 2 V -1 s -1 By adjusting the size of the CN quantum dots, photoluminescence of about 400 to 900 nm can be achieved. CN quantum dots can realize electron injection by hydrogenation, and have ferromagnetic long-range properties below 96 Kelvin. Order emerges, the presence of a band gap compensates for the lack of an intrinsic band gap in graphene, the injection of hydrogen carriers provides a new avenue for tuning the electronic properties of the material, and ferromagnetism portends a wealth of physical implications for this material system.
[0015] The N content in the carbon-nitrogen fluorescent quantum dots is 0.5 to 5 at %. The N content in the carbon-nitrogen fluorescent quantum dots can be in any range of 0.5 to 1.5 at %, 1.5 to 2.5 at %, 2.5 to 3.5 at %, 3.5 to 4.5 at %, or 4.5 to 5 at %.
[0016] The carbon-nitrogen fluorescent quantum dots have a diameter of 1 to 100 nm, which can be selected from the range of 1 to 10 nm, 10 to 20 nm, 20 to 30 nm, 30 to 40 nm, 40 to 50 nm, 50 to 60 nm, 60 to 70 nm, 70 to 80 nm, 80 to 90 nm, or 90 to 100 nm.
[0017] In one embodiment, the carbon-nitrogen fluorescent quantum dots have a quantum yield of 0.1 to 0.9.
[0018] In one embodiment, the carbon-nitrogen fluorescent quantum dots have an excitation wavelength in the range of 240-650 nm and / or an emission wavelength in the range of 350-950 nm.
[0019] In one embodiment, the surface of the carbon-nitrogen fluorescent quantum dots does not need to be modified.
[0020] In one embodiment, the use is in the manufacture of a live cell aerobic glycolysis detection product.
[0021] In one embodiment, the use is in the manufacture of a single cell aerobic glycolysis detection product.
[0022] Furthermore, the living cell or single cell is a living cell or single cell of an aerobic glycolytic metabolic model.
[0023] Furthermore, the live cell or single cell of the aerobic glycolytic metabolism model is a live tumor cell or a single tumor cell.
[0024] The carbon-nitrogen fluorescent quantum dots bind to oxidized nicotinamide adenine dinucleotide (NAD), an intermediate in the aerobic glycolytic metabolism of cells.+ Fluorescence enhancement can be achieved by fluorescence resonance energy transfer with
[0025] The aerobic glycolysis detection product is NAD + In other words, the above method detects aerobic glycolysis by detecting NAD in living cells. + The present invention relates to use in the manufacture of a product for detecting
[0026] In addition, the living cell or single cell may further comprise NAD + The tumor cell is a live tumor cell or a single tumor cell capable of producing the tumor.
[0027] The aerobic glycolysis detection product is a reagent, and based on the final volume of the reagent, the reagent contains carbon-nitrogen fluorescent quantum dots at a final concentration of 1 μg / mL to 1 mg / mL.
[0028] The reagent further includes a buffer solution. That is, the buffer solution serves as a solvent for the carbon-nitrogen fluorescent quantum dots. The buffer solution is selected from one or more of physiological saline, water, DMSO, DMF, and PBS. The pH of PBS is 7.2 to 7.4.
[0029] The present invention further relates to NAD + The present invention provides a method for producing a sensing product using a carbon-nitrogen fluorescent quantum dot.
[0030] The present invention further provides an aerobic glycolysis detection product, the aerobic glycolysis detection product comprising the carbon-nitrogen fluorescent quantum dots.
[0031] The carbon-nitrogen fluorescent quantum dots are selected from one or more of N-doped graphene quantum dots, C3N4 quantum dots, C2N quantum dots, or C3N quantum dots.
[0032] The aerobic glycolysis detection product further includes a buffer, which can be a solvent for the carbon-nitrogen fluorescent quantum dots.
[0033] The buffer is selected from one or more of saline, water, DMSO, DMF or PBS.
[0034] The present invention further provides the use of carbon-nitrogen fluorescent quantum dots in the manufacture of a product for detecting or treating a tumor.
[0035] The tumor detection product is used for early diagnosis of tumors. Specifically, the tumor detection product is used for screening tumor cells, detecting tumor micro-lesions, screening test of clinical sample tumor cells or tumor visualization research.
[0036] The tumor treatment product is used for early intervention of tumors.
[0037] The tumor cell detection product includes at least carbon-nitrogen fluorescent quantum dots.
[0038] The present invention provides a method for detecting aerobic glycolysis, which includes the steps of co-incubating a test sample with an aerobic glycolysis detection product containing carbon-nitrogen fluorescent quantum dots, and detecting the presence or absence of fluorescence generation or the intensity of the fluorescence in the test sample after the incubation is completed.
[0039] In one embodiment, the above method further includes the steps of centrifuging the culture medium after completion of the culture, discarding the supernatant, resuspending the precipitate using a buffer, and again detecting the presence or absence of fluorescence generation or the fluorescence intensity after resuspension.
[0040] It further includes one or more of the following features.
[0041] 1) The test sample is a sample containing living cells having aerobic glycolytic metabolic characteristics. Preferably, the test sample is selected from cells, tumor tissue or non-tumor tissue, pleural and ascites fluid, blood, and urine. More preferably, the test sample is a pretreated sample.
[0042] 2) The working volume of the aerobic glycolysis detection product is 1 μL to 1 mL.
[0043] 3) The incubation time is 5 min to 2 h.
[0044] 4) The culture temperature is 4 to 50°C, and preferably, the culture temperature is 20 to 40°C.
[0045] 5) When detecting the fluorescence intensity, the excitation wavelength for fluorescence detection is 200 to 800 nm.
[0046] 6) The rotation speed of the centrifuge is 500 to 1500 rpm, and the centrifugation time is 1 to 30 minutes.
[0047] In one embodiment, the pretreatment step of the test sample may include the following steps 1 and 2.
[0048] In step 1, the collected tissue was divided into 1 mm 3 Alternatively, the collected cells, pleural and ascites fluid, blood, or urine are centrifuged and the supernatant is discarded.
[0049] In step 2, a buffer solution is added to resuspend the tissue fragments or precipitate obtained in step 1. The resuspension thus obtained can be mixed with and cultured with the aerobic glycolysis detection product.
[0050] In one embodiment, the buffer used in step 2 during pretreatment of the test sample is the same as the buffer in the aerobic glycolysis detection product.
[0051] In one embodiment, a fluorescent microscope can be used to detect the presence or absence of fluorescence production. Cells undergoing aerobic glycolysis may fluoresce.
[0052] A fluorescence spectrophotometer can be used to detect the fluorescence intensity. Based on the obtained fluorescence intensity, a semi-quantitative analysis can be performed on the sample.
[0053] In one embodiment, the excitation wavelength of the fluorescence microscope is 200 to 800 nm.
[0054] Generally, the method for detecting aerobic glycolysis includes diagnostic and non-diagnostic purposes. Preferably, the method for detecting aerobic glycolysis is for non-diagnostic purposes. The non-diagnostic purpose refers to detecting aerobic glycolysis in scientific research to realize research on the mechanism of aerobic glycolysis, the mechanism of disease occurrence and progression, the mechanism of cell metabolism, etc.
[0055] Hereinafter, the embodiments of the present invention will be described through specific examples. Those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. Furthermore, the present invention can be implemented or applied by other different specific embodiments. In addition, each detail of this specification can be supplemented or modified in various ways based on different viewpoints and applications without departing from the spirit of the present invention.
[0056] Before further describing the specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific specific implementation described below. Furthermore, it should be understood that the terms used in the examples of the present invention are for describing specific specific implementations, and do not limit the scope of protection of the present invention. In addition, in the description and claims of the present invention, the singular forms such as "one", "an" and "this" include the plural forms, unless otherwise specified.
[0057] When a numerical range is given in the examples, it should be understood that any two endpoints of each numerical range and any numerical value between the two endpoints can be selected, unless otherwise specified in the present invention. In addition, unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as commonly understood by those skilled in the art. Furthermore, in addition to the specific methods, devices, and materials used in the examples, the present invention may be realized using any method, device, and material in the prior art that is similar or equivalent to the method, device, and material described in the examples of the present invention, based on the understanding of the prior art by those skilled in the art and the description of the present invention.
[0058] The method for producing the C3N quantum dots used in the following examples is as follows: 80 mL of 2,3-diaminophenazine solution (2.0 mM) was added to a 100 mL autoclave. The product was obtained by heating the mixture at a high temperature of 380°C for 16 hours. The product was then filtered through an aluminum oxide membrane with a nanopore size of 0.02 μm, and the filtrate was left to stand for 12 hours to obtain the product C3N quantum dots that can be directly used in biological experiments. The 2,3-diaminophenazine (DAP, 98%) used above was purchased from J&K Scientific ltd., USA. EXAMPLES
[0059] Solutions of multiple types of cellular metabolic intermediates (all in 0.9% saline) were selected as test samples. The multiple types of cellular metabolic intermediates were glucose, PKM1, PKM2, Pyr, LDH, lactate, NADH, and NAD, respectively. + , ADP, O2 - The compounds were , ·OH, etc. (all at 0.1 mM concentration). C3N quantum dots (diameter 1 nm, concentration 1 μg / mL, solvent saline) were selected as the product for detecting aerobic glycolysis. 1 μL of C3N quantum dots was added to the test sample, and the sample was incubated for 2 h. The incubation temperature was 25°C. The fluorescence intensity was read with the excitation wavelength of 400 nm and the emission wavelength of 530 nm of the fluorescence spectrophotometer. As a result, as shown in Figure 1, NAD + The fluorescence intensity of the sample was enhanced by about 7-fold, while no obvious change was observed in the fluorescence intensity of the remaining samples.
[0060] Then, NAD + A solution (concentration 0.1 mM) and a C3N quantum dot solution (1 μg / mL) were selected as test samples, and the excitation and emission spectra of the fluorescence emission of the two types of solutions were detected. As a result, as shown in Figure 2, +The excitation and emission wavelengths of the solution were 423 nm and 476 nm, respectively, and the excitation and emission wavelengths of the C3N quantum dot solution were 495 nm and 530 nm, respectively. + was found to be the donor and C3N quantum dots were found to be the acceptor.
[0061] These results suggest that C3N quantum dots can promote the synthesis of NAD, an intermediate in the aerobic glycolysis of cells. + It was revealed that fluorescence enhancement can be achieved by fluorescence resonance energy transfer with EXAMPLES
[0062] NAD + The solutions were selected as test samples. The concentrations were 0 mM (physiological saline), 0.05 mM, 0.1 mM, 0.15 mM, 0.2 mM, and 0.25 mM, respectively. C3N quantum dots (diameter 1 nm, concentration 1 μg / mL, solvent is physiological saline) were selected as a product for detecting aerobic glycolysis. 1 μL of C3N quantum dots was added to the test sample, and the sample was cultured for 2 h. The culture temperature was 25°C. The fluorescence intensity was then read using a fluorescence spectrophotometer. As a result, as shown in Figure 3, the fluorescence intensity of the C3N quantum dots was significantly higher than that of NAD in a certain range. + It was found to be enhanced with increasing concentration. EXAMPLES
[0063] A375 cells (aerobic glycolysis model) and fibroblasts (oxidative phosphorylation model) were selected as test samples and co-cultured. The cell concentration was 10 3The number of cells was 1. Also, C3N quantum dots (diameter 1 nm, concentration 1 μg / mL, solvent is saline) were selected as the product for detecting aerobic glycolysis. 1 μL of C3N quantum dots was added to the test sample, and the sample was cultured for 2 h. The culture temperature was 25°C. Then, the fluorescence status of the sample was observed under a fluorescence microscope (excitation wavelength 400 nm). As a result, as shown in Figure 4, the fluorescence of A375 cells in the field of view was clear, but no obvious fluorescence was observed in fibroblasts. The cells marked with dotted circles are A375 cells, and the cells marked with solid circles are fibroblasts. EXAMPLES
[0064] A375 cells were selected as the test samples. The cell concentration was 10 5 There were 100 pieces. 1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one (PFK15, 20 nM) was added to the test cell sample and cultured for 12 hours. In addition, C3N quantum dots (diameter 1 nm, concentration 1 μg / mL, solvent is saline) were selected as a product for detecting aerobic glycolysis. 1 μL of C3N quantum dots was added to the test sample and cultured for 12 hours. The culture temperature was 25°C. Then, the fluorescence state was observed under a fluorescence microscope (excitation wavelength 400 nm), and it was found that the treatment with PFK15 (PFK15 can inhibit the aerobic glycolysis metabolism level of cells and increase the NAD in the cytoplasm) + The fluorescence of A375 cells treated with PFK15 (reducing the concentration) was reduced by 43% compared to the group not treated with PFK15 (results shown in Figure 5). EXAMPLES
[0065] BALB / c nude mice (4 weeks, female) were selected and anesthetized with 3% pentobarbital. A375 cells were then cultured at a concentration of 2 × 10 8 mL -1The tumor cells were placed in a suspension of CN quantum dots. Then, the tumor cells were injected into the subvitreous space of the mouse to prepare an intraocular intraepithelial tumor animal model. One week after the tumor cell injection, the prepared C3N quantum dot solution was injected into the subvitreous space and cultured for 12 hours, after which small animal live imaging was performed. The rats were then sacrificed, and the ocular tissues were collected and sliced, followed by HE staining and fluorescence photography. As a result, the process of tumor cell growth was visible in both HE staining, fluorescence photography, and small animal live imaging, as shown in Figure 6. As a result, it was shown that carbon-nitrogen fluorescent quantum dots enable accurate dynamic fluorescent labeling and observation of the growth process of tumor cells in an aerobic glycolysis metabolic model in the animal body. EXAMPLES
[0066] Urine from bladder cancer patients and healthy subjects were selected as test samples. In addition, C3N quantum dots (diameter 1 nm, concentration 1 μg / mL, solvent is saline) were selected as the product for detecting aerobic glycolysis. 1 μL of C3N quantum dots was added to the test sample, and the sample was incubated for 2 h. The incubation temperature was 25°C. Then, the fluorescence status of the sample was observed under a fluorescence microscope (excitation wavelength 400 nm). As a result, as shown in Figure 7, the urine cells of the tumor patients in the field of view were clearly fluorescent, but no obvious fluorescence was observed in the urine of the healthy subjects.
[0067] The above examples are for illustrating the implementation of the present invention and should not be construed as limiting the present invention. In addition, the various modifications and variations of the methods of the invention listed herein are obvious to those skilled in the art, provided that they do not deviate from the scope and spirit of the present invention. Although the present invention has been specifically described by combining several specific preferred embodiments of the present invention, it should be understood that the present invention is not limited to these specific embodiments. In fact, the inventions obtained by the above modifications that are obvious to those skilled in the art are all included in the scope of the present invention.
Claims
1. 1. Use of carbon-nitrogen fluorescent quantum dots in the manufacture of an aerobic glycolysis detection product, comprising: The carbon-nitrogen fluorescent quantum dots are C 3 N quantum dots, and the N content in the carbon-nitrogen fluorescent quantum dots is 0.5 to 5 at %; The aerobic glycolysis detection product detects NAD + by measuring by fluorescence resonance energy transfer, and thus can detect aerobic glycolysis; In said fluorescence resonance energy transfer, NAD + is the donor and C 3 N quantum dots are the acceptor.
2. The use according to claim 1, characterized in that the carbon-nitrogen fluorescent quantum dots have a diameter of 1-100 nm.
3. The use according to claim 1, characterized in that the use is in the manufacture of a product for detecting aerobic glycolysis in living cells.
4. The use described in claim 1, characterized in that the use is in the manufacture of a product for qualitative or semi-quantitative detection of aerobic glycolysis.
5. The use according to claim 1, characterized in that the aerobic glycolysis detection product is a reagent, and the reagent contains carbon-nitrogen fluorescent quantum dots at a final concentration of 1 μg / mL to 1 mg / mL based on the final volume of the reagent.
6. 6. The use according to claim 5, wherein the reagent further comprises a buffer, the buffer being selected from one or more of saline, water, DMSO, DMF or PBS.
7. NAD + 1. Use of carbon-nitrogen fluorescent quantum dots in the manufacture of a detection product, comprising: The carbon-nitrogen fluorescent quantum dots are C 3 N quantum dots, and the N content in the carbon-nitrogen fluorescent quantum dots is 0.5 to 5 at %; The NAD + detection product is capable of detecting NAD + by measurement using fluorescence resonance energy transfer; In said fluorescence resonance energy transfer, NAD + is the donor and C 3 N quantum dots are the acceptor.
8. 1. A method for detecting aerobic glycolysis, comprising: The method includes the steps of co-culturing an aerobic glycolysis detection product containing carbon-nitrogen fluorescent quantum dots with a test sample, and detecting the presence or absence of fluorescence generation or the intensity of the fluorescence after the end of the culture, The carbon-nitrogen fluorescent quantum dots are C 3 N quantum dots, and the N content in the carbon-nitrogen fluorescent quantum dots is 0.5 to 5 at %; The aerobic glycolysis detection product detects NAD + by measuring by fluorescence resonance energy transfer, and thus can detect aerobic glycolysis; The method is characterized in that in the fluorescence resonance energy transfer, NAD + is the donor and C 3 N quantum dots are the acceptor.
9. The method according to claim 8, further comprising the steps of centrifuging the culture medium after completion of the culture, discarding the supernatant, resuspending the precipitate using a buffer, and detecting again the presence or absence of fluorescence generation or the intensity of fluorescence after resuspension.
10. Furthermore, 1) The test sample is a sample containing living cells having aerobic glycolytic metabolic characteristics; 2) the working volume of the aerobic glycolysis detection product is 1 μL to 1 mL; 3) The culture time is 5 min to 2 h. 4) The culture temperature is 4 to 50°C; 5) When detecting the fluorescence intensity, the excitation wavelength for fluorescence detection is 200 to 800 nm; 9. The method of claim 8, comprising one or more of the following features:
11. The method according to claim 8, characterized in that the test sample is selected from cells, tumor tissue or non-tumor tissue, pleural and ascites fluid, blood or urine.
12. The method according to claim 8, wherein the test sample is a pretreated sample.
Citation Information
Patent Citations
N-CQDs (nitrogen-doped carbon quantum dots) with high fluorescence quantum yield as well as preparation method and application of N-CQDs
CN105802621A
Melem-modified g-C3N4 blue fluorescent powder as well as preparation method and application thereof
CN107502338A
Graphene quantum dots and method of making
US20150284318A1
Rapid detection test for SARS-COV-2
WO2021156878A2
Ultra-high-throughput microfluidic enzyme screening platform for enzyme development
WO2021209818A1
